Umbilical Cord Mesenchymal Stammzellen Therapy for Diabetic Nephropathy
Brief Summary:
This clinical trial assessed the safety of human umbilical cord mesenchymal Stammzelltherapie In 15 patients with diabetic nephropathy. Fifteen subjects received umbilical cord mesenchymal Stammzelltherapie 3 times. Etwa 1 × 106/kg of human umbilical cord mesenchymal stem cells were administered by peripheral intravenous infusion once a month .Endpoints:Primary endpoint: Safety and adverse events (safety and tolerability of umbilical cord mesenchymal Stammzelltherapie within 60 Wochen).Secondary endpoint indicators:Efficacy measures: eGFR, urinary albumin-to-creatinine ratio, and percentage changes of 24-h urinary protein quantities from baseline to 60 Wochen.
